Developing SHP2-based combination therapy for KRAS-amplified cancer
Gastroesophageal adenocarcinomas (GEAs) harbor recurrent amplification of KRAS, leading to marked overexpression of WT KRAS protein. We previously demonstrated that SHP2 phosphatase, which acts to promote KRAS and downstream MAPK pathway activation, is a target in these tumors when combined with MEK...
Tallennettuna:
| Päätekijät: | , , , , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Clinical investigation
2023-02-01
|
| Sarja: | JCI Insight |
| Aiheet: | |
| Linkit: | https://doi.org/10.1172/jci.insight.152714 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|